ATE361067T1 - Naphtoquinone derivate als inhibitoren von tau aggregation zur behandlung von alzheimer's und verbundenen neurodegenerativen erkrankungen - Google Patents

Naphtoquinone derivate als inhibitoren von tau aggregation zur behandlung von alzheimer's und verbundenen neurodegenerativen erkrankungen

Info

Publication number: ATE361067T1
Authority: AT; Austria
Prior art keywords: alzheimer; treatment; neurodegenerative diseases; inhibitors; tau aggregation
Prior art date: 2001-07-16

Application number

AT02745640T

Other languages

English (en)

Inventor

Claude M Wischik

David Horsley

Janet E Rickard

Charles R Harrington

Original Assignee

Wista Lab Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-07-16

Filing date

2002-07-16

Publication date

2007-05-15

2002-07-16 Application filed by Wista Lab Ltd filed Critical Wista Lab Ltd

2007-05-15 Application granted granted Critical

2007-05-15 Publication of ATE361067T1 publication Critical patent/ATE361067T1/de

Links

208000015122 neurodegenerative disease Diseases 0.000 title abstract 3
238000004220 aggregation Methods 0.000 title abstract 2
230000002776 aggregation Effects 0.000 title abstract 2
238000011282 treatment Methods 0.000 title abstract 2
239000003112 inhibitor Substances 0.000 title 1
150000001875 compounds Chemical class 0.000 abstract 4
MJVAVZPDRWSRRC-UHFFFAOYSA-N Menadione Chemical compound C1=CC=C2C(=O)C(C)=CC(=O)C2=C1 MJVAVZPDRWSRRC-UHFFFAOYSA-N 0.000 abstract 2
230000004770 neurodegeneration Effects 0.000 abstract 2
208000024827 Alzheimer disease Diseases 0.000 abstract 1
206010012289 Dementia Diseases 0.000 abstract 1
241000276398 Opsanus tau Species 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
238000011321 prophylaxis Methods 0.000 abstract 1
102000004169 proteins and genes Human genes 0.000 abstract 1
108090000623 proteins and genes Proteins 0.000 abstract 1
235000012711 vitamin K3 Nutrition 0.000 abstract 1
239000011652 vitamin K3 Substances 0.000 abstract 1
229940041603 vitamin k 3 Drugs 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Epidemiology (AREA)
Diabetes (AREA)
Emergency Medicine (AREA)
Hematology (AREA)
Psychology (AREA)
Endocrinology (AREA)
Hospice & Palliative Care (AREA)
Communicable Diseases (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Oncology (AREA)
Psychiatry (AREA)
Obesity (AREA)
Gastroenterology & Hepatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

AT02745640T 2001-07-16 2002-07-16 Naphtoquinone derivate als inhibitoren von tau aggregation zur behandlung von alzheimer's und verbundenen neurodegenerativen erkrankungen ATE361067T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
GBGB0117326.9A GB0117326D0 (en)	2001-07-16	2001-07-16	Napthoquinone-type inhibitors of protein aggregation

Publications (1)

Publication Number	Publication Date
ATE361067T1 true ATE361067T1 (de)	2007-05-15

Family

ID=9918593

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT02745640T ATE361067T1 (de)	2001-07-16	2002-07-16	Naphtoquinone derivate als inhibitoren von tau aggregation zur behandlung von alzheimer's und verbundenen neurodegenerativen erkrankungen

Country Status (12)

Country	Link
US (1)	US7605179B2 (de)
EP (1)	EP1408952B1 (de)
JP (1)	JP5147157B2 (de)
CN (1)	CN1313088C (de)
AT (1)	ATE361067T1 (de)
AU (1)	AU2002317354B2 (de)
CA (1)	CA2451422C (de)
DE (1)	DE60219917T2 (de)
ES (1)	ES2287292T3 (de)
GB (1)	GB0117326D0 (de)
SG (1)	SG148846A1 (de)
WO (1)	WO2003007933A1 (de)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9506197D0 (en)	1995-03-27	1995-05-17	Hoffmann La Roche	Inhibition of tau-tau association.
GB0100119D0 (en)	2001-01-03	2001-02-14	Univ Aberdeen	Materials and methods relating to protein aggregation in neurodegenerative disease
GB0101049D0 (en)	2001-01-15	2001-02-28	Univ Aberdeen	Materials and methods relating to protein aggregation in neurodegenerative disease
GB0106953D0 (en)	2001-03-20	2001-05-09	Univ Aberdeen	Neufofibrillary labels
CA2528627A1 (en) *	2003-06-23	2005-01-06	Neurochem (International) Limited	Treatment of protein aggregation disorders
WO2005053609A2 (en) *	2003-11-26	2005-06-16	Guilford Pharmaceuticals Inc.	Methods of nad+-dependent deacetylase inhibitors
WO2006007864A1 (en) *	2004-07-17	2006-01-26	Max Planck Geselllschaft Zur Förderung Der Wissenschaft	Treating neurodegenerative conditions
FR2874923B1 (fr) *	2004-09-07	2006-10-27	Trophos Sa	Application a titre de medicaments de derives du 3, 5-seco-4-nor-cholestane, compositions pharmaceutiques les renfermant, nouveaux derives et leur procede de preparation
CN101084204B (zh)	2004-09-23	2012-12-05	卫思道制药有限公司	包括亚甲蓝(mtc)在内的二氨基吩噻嗪鎓化合物的化学合成和纯化方法
JP4734602B2 (ja)	2004-12-21	2011-07-27	Ｄｏｗａエレクトロニクス株式会社	保存安定性に優れた窒化鉄系磁性粉末
JP4822312B2 (ja) *	2005-05-13	2011-11-24	学校法人慶應義塾	ナフトキノン誘導体化合物
KR100699945B1 (ko) *	2005-11-24	2007-03-26	(주) 디지탈바이오텍	나프토퀴논계 화합물을 함유하는 인지기능 장애의 예방 및 치료용 조성물
SI2004155T1 (en)	2006-03-29	2018-05-31	Wista Laboratories Ltd.	Inhibitors of protein aggregation
ES2349322T7 (es)	2006-03-29	2019-10-17	Wista Lab Ltd	Sales de 3,7-diamino-10H-fenotiazina y su utilización
US20110201686A1 (en) *	2006-06-23	2011-08-18	Yousef Al-Abed	Inhibitors of ASS and Synuclein Aggregation
EP2130533A4 (de)	2007-04-05	2010-04-21	J Oil Mills Inc	Ataraktikum und funktionelles nahrungsmittel
WO2009033151A1 (en) *	2007-09-07	2009-03-12	The Trustees Of Columbia University In The City Of New York	Tau protein screening assay
EP2060256A1 (de) *	2007-11-16	2009-05-20	Gnosis S.p.A.	Auf Menaquinolen basierende pharmazeutische und nutrazeutische Zusammensetzungen
GB0816269D0 (en) *	2008-09-05	2008-10-15	Univ Ramot	Naphthoquinone derivatives useful for prevention of amyloid deposits and treatment of alzheimers disease
JP2013529181A (ja)	2010-03-25	2013-07-18	ザジェイ．デヴィッドグラッドストーンインスティテューツ	神経障害を治療するための組成物および方法
US9320793B2 (en) *	2010-07-14	2016-04-26	Acumen Pharmaceuticals, Inc.	Method for treating a disease associated with soluble, oligomeric species of amyloid beta 1-42
SG187744A1 (en) *	2010-08-06	2013-03-28	Edison Pharmaceuticals Inc	Treatment of mitochondrial diseases with naphthoquinones
US20120244174A1 (en)	2011-01-31	2012-09-27	Intellect Neurosciences Inc.	Treatment of tauopathies
JP5898701B2 (ja)	2011-02-11	2016-04-13	ウィスタラボラトリーズリミテッド	フェノチアジンジアミニウム塩およびそれらの使用
EP2699157B1 (de)	2011-04-21	2018-03-14	The Regents of The University of California	Funktionalisierte magnetische nanoteilchen und ihre verwendung bei der abbildung von amyloider plaque und neurofibrillären bündeln
WO2012170773A1 (en) *	2011-06-08	2012-12-13	Edison Pharmaceuticals, Inc.	Adjunctive therapy for the treatment of mitochondrial disorders with quinones and naphthoquinones
EP2764863B1 (de)	2011-10-03	2020-03-11	National Center for Geriatrics and Gerontology	Tau-aggregationshemmer
WO2013115867A1 (en)	2012-02-05	2013-08-08	Biodesy, Llc	Methods for identifying modulators of ras using nonlinear techniques
NZ630542A (en)	2012-08-16	2017-06-30	Ipierian Inc	Methods of treating a tauopathy
CA2883882A1 (en)	2012-09-07	2014-03-13	Ptc Therapeutics, Inc.	Benzoquinone derivatives for treating oxidative stress disorders
EP3722320A3 (de)	2012-10-25	2020-12-30	Bioverativ USA Inc.	Anti-komplement-c1s-antikörper und verwendungen davon
DK2914291T3 (da)	2012-11-02	2022-05-16	Bioverativ Usa Inc	Anti-komplement-c1s-antistoffer og anvendelser deraf
EP2962687B1 (de)	2013-04-02	2019-06-05	The Doshisha	Tau-aggregationshemmer
BR112015030356A2 (pt)	2013-06-10	2017-12-05	Ipierian Inc	métodos de tratamento de uma taupatia
JP6518656B2 (ja) *	2013-06-13	2019-05-22	バイオデシー，インコーポレイテッド	標的生体実体を標的にする生化学実体候補をスクリーニングする方法
US20150166476A1 (en) *	2013-12-17	2015-06-18	Yi-Cheng Chen	Methods for treating neurodegenerative diseases associated with aggregation of amyloid-beta
WO2016106286A1 (en)	2014-12-23	2016-06-30	Biodesy, Inc.	Attachment of proteins to interfaces for use in nonlinear optical detection
US11628147B2 (en)	2017-12-19	2023-04-18	Synergia Life Sciences Pvt. Ltd.	Vitamin K2 compositions for the treatment of drug induced neuropathy
BR112020019832A2 (pt)	2018-03-30	2021-01-05	Kaydence Pharma As	Métodos para melhorar função cardiovascular, elasticidade, velocidade de onda de pulso ou disfunção endotelial, reduzir rigidez arterial e/ou para reverter calcificação de um vaso sanguíneo em um mamífero e para aumentar produção de óxido nítrico endotelial em um sujeito, e, kit
WO2020201828A1 (en)	2019-04-05	2020-10-08	Tauc3 Biologics Limited	Anti-tauc3 antibodies and uses thereof
CN110025624B (zh) *	2019-05-29	2021-04-02	济宁医学院附属医院	萘醌苷类化合物在老年痴呆中的应用及其药物制备
CN112778092B (zh) *	2020-12-31	2023-03-24	玉溪健坤生物药业有限公司	一种还原型维生素k2的制备方法及其用途

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS59175449A (ja) *	1983-03-26	1984-10-04	Kyushu Kogyo Daigaku	シコニンの製造法
JPS61143334A (ja) *	1984-12-18	1986-07-01	Mitsui Petrochem Ind Ltd	５，８−ジヒドロキシ−１，４−ナフトキノン誘導体
US4897388A (en) *	1988-12-20	1990-01-30	Geriatric Research Institute, Inc.	Method of treating Alzheimer's disease
ATE194283T1 (de) *	1991-02-04	2000-07-15	Ks Biomedix Ltd	Naphtochinonderivate zur behandlung von chronischen entzündungen
DK0618968T3 (da)	1991-12-06	2000-04-10	Max Planck Gesellschaft	Midler til diagnostisering og behandling af Alzheimer's sygdom
AU708682B2 (en)	1994-08-08	1999-08-12	Albert Einstein College Of Medicine Of Yeshiva University	Methods for treating and/or preventing Alzheimer's disease using phenothiazines and/or thioxanthenes
JPH08193026A (ja) *	1995-01-12	1996-07-30	Teijin Ltd	アミロイドβ蛋白凝集・沈着阻害剤
DE19504003A1 (de) *	1995-02-08	1996-08-14	Martin Dr Kohlmeier	Verwendungen eines Vitamins der K-Gruppe
GB9506197D0 (en)	1995-03-27	1995-05-17	Hoffmann La Roche	Inhibition of tau-tau association.
US5804601A (en)	1995-04-10	1998-09-08	Takeda Chemical Industries, Ltd.	Aromatic hydroxamic acid compounds, their production and use
KR0180791B1 (ko) *	1995-07-24	1999-05-15	김용옥	6-치환-5,8-디옥시-1,4-나프토퀴논 유도체, 그의 제조방법 및 그의 항암제로서의 용도
JP3809014B2 (ja) *	1998-05-22	2006-08-16	花王株式会社	養毛・育毛剤
US20020040011A1 (en)	2000-06-01	2002-04-04	Brown Dennis M.	Naphthoquinone compositions and uses thereof
US20020016372A1 (en)	2000-07-31	2002-02-07	Allison Anthony Clifford	Method for preventing and treating alzheimer's disease and brain damage associated with cardiov ascular disease and head injury
GB0100119D0 (en)	2001-01-03	2001-02-14	Univ Aberdeen	Materials and methods relating to protein aggregation in neurodegenerative disease
GB0101049D0 (en)	2001-01-15	2001-02-28	Univ Aberdeen	Materials and methods relating to protein aggregation in neurodegenerative disease
GB0106953D0 (en)	2001-03-20	2001-05-09	Univ Aberdeen	Neufofibrillary labels
US6953974B2 (en) *	2003-08-26	2005-10-11	Texas Instruments Incorporated	EEPROM device and method for providing lower programming voltage
GB0322756D0 (en)	2003-09-29	2003-10-29	Univ Aberdeen	Methods of chemical synthesis
SI2322517T1 (sl)	2004-09-23	2019-06-28	Wista Laboratories Ltd.	Postopki za kemijsko sintezo in čiščenje diaminofenotiazinijevih spojin, vključno metiltioninijevega klorida (MTC)

2001
- 2001-07-16 GB GBGB0117326.9A patent/GB0117326D0/en not_active Ceased
2002
- 2002-07-16 ES ES02745640T patent/ES2287292T3/es not_active Expired - Lifetime
- 2002-07-16 WO PCT/GB2002/003269 patent/WO2003007933A1/en not_active Ceased
- 2002-07-16 CA CA2451422A patent/CA2451422C/en not_active Expired - Lifetime
- 2002-07-16 US US10/483,266 patent/US7605179B2/en not_active Expired - Lifetime
- 2002-07-16 CN CNB028177207A patent/CN1313088C/zh not_active Expired - Lifetime
- 2002-07-16 SG SG200600959-1A patent/SG148846A1/en unknown
- 2002-07-16 EP EP02745640A patent/EP1408952B1/de not_active Expired - Lifetime
- 2002-07-16 DE DE60219917T patent/DE60219917T2/de not_active Expired - Lifetime
- 2002-07-16 JP JP2003513541A patent/JP5147157B2/ja not_active Expired - Lifetime
- 2002-07-16 AT AT02745640T patent/ATE361067T1/de active
- 2002-07-16 AU AU2002317354A patent/AU2002317354B2/en not_active Expired

Also Published As

Publication number	Publication date
DE60219917T2 (de)	2008-01-17
JP2004534854A (ja)	2004-11-18
CN1313088C (zh)	2007-05-02
HK1063012A1 (en)	2004-12-10
ES2287292T3 (es)	2007-12-16
EP1408952B1 (de)	2007-05-02
WO2003007933A1 (en)	2003-01-30
CA2451422C (en)	2010-10-19
US20050107472A1 (en)	2005-05-19
GB0117326D0 (en)	2001-09-05
SG148846A1 (en)	2009-01-29
JP5147157B2 (ja)	2013-02-20
CA2451422A1 (en)	2003-01-30
CN1553800A (zh)	2004-12-08
AU2002317354B2 (en)	2007-07-19
EP1408952A1 (de)	2004-04-21
DE60219917D1 (de)	2007-06-14
US7605179B2 (en)	2009-10-20

Legal Events

Date

Code

Title

Description

2007-09-15

UEP

Publication of translation of european patent specification

Ref document number: 1408952

Country of ref document: EP

Publication	Publication Date	Title
ATE361067T1 (de)	2007-05-15	Naphtoquinone derivate als inhibitoren von tau aggregation zur behandlung von alzheimer's und verbundenen neurodegenerativen erkrankungen
ATE409176T1 (de)	2008-10-15	1-phenylalkancarbonsäurederivate zur behandlung neurodegenerativer erkrankungen
EA200900802A1 (ru)	2010-04-30	Способы и композиции для лечения амилоидных заболеваний
EA200600078A1 (ru)	2006-08-25	Способы и композиции для лечения амилоидных заболеваний
DK1465626T3 (da)	2008-11-17	Farmaceutiske præparater (kit) der omfatter dihydropyridinonforbindelser og et immunregulatorisk (eller et antiinflammatorisk) middel samt anvendelser deraf
DE122012000007I1 (de)	2012-04-12	Zusammenzetzungen und verfahren zur stabilisierungvon transthyretin und zur hemmung von transthyret infehlfaltung.
ATE506951T1 (de)	2011-05-15	Als inhibitoren von beta-secretase aktive tertiäre carbinamine mit substituierten heterocyclen zur behandlung der alzheimer- krankheit
NO20071240L (no)	2007-05-16	Terapeutiske anvendelser av RTP801 inhibitorer
WO2005004803A3 (en)	2005-04-21	Phenylcarboxylate beta-secretase inhibitors for the treatment of alzheimer's disease
NO961326D0 (no)	1996-04-01	Inhibitorer av
ATE443043T1 (de)	2009-10-15	Phenylcarboxamide als beta-sekretase-hemmer zur behandlung von alzheimer
EA200501017A1 (ru)	2006-02-24	Астма и модуляторы аллергических воспалений
ATE517861T1 (de)	2011-08-15	Benzylether und benzylaminoverbindungen als inhibitoren von beta-secretase zur behandlung von alzheimer-krankheit
ATE480235T1 (de)	2010-09-15	Verwendung von pramipexol zur behandlung von amyotrophischer lateralsklerose
EA200600071A1 (ru)	2006-08-25	Производные n-фенилпиперазина и способы профилактики или лечения заболеваний, связанных с 5ht-рецептором
NO20063193L (no)	2006-09-15	Fusjonerte pyrrolokarbazoler og fremgangsmater for fremstilling derav
NO20044530L (no)	2004-10-21	Fremgangsmate for behandling av kognitive forstyrrelser
ATE432278T1 (de)	2009-06-15	Verbindungen zur behandlung von krankheiten
NO20015247L (no)	2001-10-26	Glysinspaltingssysteminhibitorer som potensielle antipsykotika
DE602004006118D1 (de)	2007-06-06	2,3,4,5-TETRAHYDROBENZOiFöi1,4öOXAZEPIN-5-CARBONSÄUREAMID DERIVATE ALS GAMMA-SECRETASE INHIBITOREN ZUR BEHANDLUNG VON ALZHEIMER
ATE464048T1 (de)	2010-04-15	Behandlung von alzheimer-krankheit und verwandten zuständen
ATE399758T1 (de)	2008-07-15	Derivate von 1-phenylalkancarbonsäuren zur behandlung von neurodegenerativen krankheiten
BR0314541A (pt)	2005-07-26	Tratamento de demência e doença de parkinson
DE602004024992D1 (de)	2010-02-25	Verwendung von pyrazolopyridinen zur behandlung von kognitiven defiziten
ATE553114T1 (de)	2012-04-15	Verbindungen zur verminderung der aggregation von amyloid-beta-peptid